Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immune suppression in the tumor microenvironment.

Thomas F Gajewski1, Yuru Meng, Helena Harlin

  • 1Department of Pathology and Department of Medicine University of Chicago, Chicago, IL 60637, USA. tgajewsk@medicine.bsd.uchicago.edu

Journal of Immunotherapy (Hagerstown, Md. : 1997)
|May 16, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance).

Cancer immunology research·2026
Same author

Tumor Cell-Intrinsic Decr2 Regulates Ferroptosis and Immunotherapy Efficacy.

Cancer immunology research·2025
Same author

Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma.

Nature medicine·2025
Same author

Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.

Nature·2025
Same author

Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia.

Blood advances·2025
Same author

PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells.

Cancer immunology research·2025
Same journal

Internalization-Dependent EGFR-Targeted Photoactivation by Cetuximab-I21 Conjugates.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2026
Same journal

Clinical Features, Treatment, and Outcomes of Nivolumab-induced Autoimmune Hemolytic Anemia.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2026
Same journal

Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2026
Same journal

Ligand-Receptor-Based Novel TWEAK CAR-T Exhibits Potent Antitumor Activity Against Liver Cancer by Targeting FN14.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2026
Same journal

Talimogene Laherparepvec Response in Recurrent Melanoma During Corticosteroid Replacement for Immune Checkpoint Inhibitor-Induced Adrenal Insufficiency: A Case Report.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2026
Same journal

Pulsed Electrical Field Ablation Plus Intratumoral Immunotherapy for Hepatocellular Carcinoma.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2026
See all related articles

Tumor antigens enable study of T cells and immunotherapy development. However, tumor immune evasion mechanisms, particularly in the tumor microenvironment, limit clinical responses and require further investigation.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Immunotherapy

Background:

  • Tumor-expressed antigens recognized by T lymphocytes aid anti-tumor immunity research and immunotherapy development.
  • Clinical trials show increased tumor antigen-specific T cells but infrequent clinical responses, suggesting dominant resistance mechanisms.

Purpose of the Study:

  • To investigate mechanisms of immune evasion in the tumor microenvironment that limit the efficacy of anti-tumor immune responses.
  • To highlight the need for clinical studies to identify and counter these resistance mechanisms.

Main Methods:

  • Review of existing research on T cell responses to tumor antigens.
  • Analysis of clinical trial data regarding immune cell increases and clinical outcomes.
  • Examination of preclinical murine models investigating immune evasion pathways.

Related Experiment Videos

Main Results:

  • Evidence suggests T cell hyporesponsiveness, regulatory cells, inhibitory ligands (e.g., PD-L1), soluble factors (e.g., TGF-beta), and enzymes (e.g., IDO) contribute to immune escape.
  • Preclinical models demonstrate that targeting these mechanisms can enhance T cell-mediated tumor control.

Conclusions:

  • Immune evasion mechanisms within the tumor microenvironment are critical barriers to effective anti-tumor immunotherapy.
  • Prioritizing clinical studies to identify specific evasion events and develop counter-strategies is essential for improving patient outcomes.